Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    INFLAMMATORY BOWEL DISEASE 10
Show Display Options
Rank Status Study
1 Unknown  Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience
Condition: Pediatric Inflammatory Bowel Disease
Intervention:
2 Completed Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
Conditions: Iron Deficiency Anaemia;   Inflammatory Bowel Disease;   Crohn's Disease
Interventions: Drug: ST10-021;   Drug: Placebo Comparator
3 Completed Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)
Conditions: Iron Deficiency Anaemia;   Inflammatory Bowel Disease;   Ulcerative Colitis
Interventions: Drug: ST10-021;   Drug: Placebo Comparator
4 Not yet recruiting Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis
Condition: Crohn's Disease
Interventions: Procedure: Abdominal MRI;   Procedure: Upper endoscopy;   Procedure: Colonoscopy;   Procedure: Pelvic MRI
5 Completed Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: 10% Metronidazole Ointment
6 Completed Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease
Condition: Perianal Crohns'
Intervention: Drug: Metronidazole
7 Terminated
Has Results
A Study With Pentasa in Patients With Active Crohn's Disease
Condition: Crohn´s Disease
Interventions: Drug: Pentasa;   Drug: Placebo
8 Terminated
Has Results
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: AIN457;   Drug: Placebo
9 Terminated Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Placebo;   Drug: BIBR 796 BS, 5 mg;   Drug: BIBR 796 BS, 20 mg
10 Recruiting Crohn's Extent of Resection Trial
Conditions: Crohn's Disease;   Recurrence
Interventions: Procedure: Extended resection;   Procedure: Conventional resection
11 Completed A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: MDX-1100 (anti-CXCL10 human monoclonal antibody)
12 Completed A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Biological: sterile saline for injection;   Biological: MDX-1100
13 Recruiting Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)
Condition: Iron Deficiency Anaemia
Intervention: Drug: 10% Iron Isomaltoside 1000
14 Completed CESA 5.10 Investigation to Compare the Efficacy and Safety of the Adacolumn® Apheresis Device in Patients With Active Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Device: Adacolumn®
15 Completed A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis
Condition: Moderately Active Ulcerative Colitis
Interventions: Biological: AG011;   Other: Placebo
16 Completed Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer
Conditions: Colorectal Cancer;   Inflammation
Intervention: Dietary Supplement: fish oil encapsuled
17 Completed Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Conditions: Gastric Ulcers;   Duodenal Ulcers
Interventions: Drug: TAK-438;   Drug: Placebo;   Drug: Lansoprazole
18 Completed Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Conditions: Gastric Ulcers;   Duodenal Ulcers
Interventions: Drug: TAK-438;   Drug: Placebo;   Drug: Lansoprazole

Study has passed its completion date and status has not been verified in more than two years.